Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.34 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29307524 | 1.00 | CYP17A1 (0.40) | CYP17A1GPR84RXFP1MAPTSMN1; SMN2 | |
| SCHEMBL25025555 | 0.88 | HTR1A (0.38) | CYP17A1RXFP1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL25025551 | 0.83 | MAPT (0.38) | CYP17A1RXFP1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL30218688 | 0.76 | GABRA1 (0.44) | GPR84RXFP1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL30218670 | 0.76 | MAPT (0.42) | RXFP1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL23168153 | 0.76 | CYP17A1 (0.39) | CYP17A1GPR84RXFP1MAPTSMN1; SMN2 | |
| SCHEMBL31324602 | 0.76 | CYP17A1 (0.39) | CYP17A1GPR84RXFP1MAPTSMN1; SMN2 | |
| Water SCHEMBL28521947 | 0.75 | GABRA1 (0.44) | GPR84RXFP1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL30218664 | 0.74 | NR4A2 (0.52) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL31146152 | 0.73 | CYP17A1 (0.44) | CYP17A1RXFP1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119301100-A | Novel 1, 2-diaminobenzimidazole derivatives | 卡尔那生物科学株式会社 | 2025-01-10 | — | — | CN | disclosed |
| US-12037325-B2 | 1,2-diaminobenzimidazole derivative | CARNA BIOSCIENCES, INC. (JP) | 2024-07-16 | — | — | US | disclosed |
| EP-4373811-A1 | NOVEL 1,2-DIAMINOBENZIMIDAZOLE DERIVATIVE | Carna Biosciences, Inc. (JP) | 2024-05-29 | — | — | EP | disclosed |
| US-20230097964-A1 | NOVEL 1,2-DIAMINOBENZIMIDAZOLE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2023-03-30 | — | — | US | disclosed |
| WO-2023002246-A1 | NOVEL 1,2-DIAMINOBENZIMIDAZOLE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037325-B2 | 1,2-diaminobenzimidazole derivative | STING1, TBK1, IRF3 | CYP17A1 4046/4885GPR84 219/4885RXFP1 630/4885 |
| US-20230097964-A1 | NOVEL 1,2-DIAMINOBENZIMIDAZOLE DERIVATIVE | STING1, IRF3, TBK1 | CYP17A1 3784/4885GPR84 319/4885RXFP1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.